Consequently, capivasertib has become the first FDA-approved AKT inhibitor for use in HR-positive and HER2-negative breast cancer patients with one or more PIK3CA/AKT1/PTEN alterations [31]. This evidence concerns the gene ERBB2 and breast carcinoma.